author-photo

Mauro Presti

University of Milan

11

Papers

655

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

A multicenter, randomized, phase III study comparing paclitaxel/carboplatin (PC) versus topotecan/paclitaxel/carboplatin (TPC) in patients with stage III (residual tumor > 1 cm after primary surgery) and IV ovarian cancer (OC)

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (18)
Paclitaxel 175 or 225 mg per Meters Squared With Carboplatin in Advanced Ovarian Cancer: A Randomized Trial

2004 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (31)
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupAnn Oncol 2003; 14: 441–448

2003 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

2003 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (168)
Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

2001 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (84)
Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin

1989 Journal of the National Cancer Institute
Show All
- Source
- Cite
- Save
Citations (117)
CA 125 reliability in predicting ovarian cancer recurrence.

1989 Tumori
Show All
- Source
- Cite
- Save
Citations (7)
Analysis of 309 cases after hydatidiform mole: Different follow-up program according to biologic behavior

1988 Tumori
Show All
- Source
- Cite
- Save
Citations (5)
Tumor antigen CA 125 as a marker of ovarian epithelial carcinoma

1987 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (39)